EGFR and metastatic colorectal cancer: Corresponding clinical trials have been conducted in a population of chemotherapy-refractory metastatic colorectal cancer patients, demonstrating that the combination of cetuximab (anti-EGFR monoclonal antibody) and KRASG12C inhibitor adagrasib is more effective than adagrasib monotherapy137.